These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 23703296)

  • 1. Safety of second-line chemotherapy with non-conventional fotemustine schedule in recurrent high grade gliomas: a single institution experience.
    Gaviani P; Simonetti G; Salmaggi A; Lamperti E; Silvani A
    J Neurooncol; 2013 Jul; 113(3):527-9. PubMed ID: 23703296
    [No Abstract]   [Full Text] [Related]  

  • 2. GEINOFOTE: efficacy and safety of fotemustine in patients with high-grade recurrent gliomas and poor performance status.
    Pérez-Segura P; Manneh R; Ceballos I; García A; Benavides M; Fuster J; Vaz MA; Cano JM; Berros JP; Covela M; Moreno V; Quintanar T; García Bueno JM; Fernández I; Sepúlveda J
    Clin Transl Oncol; 2016 Aug; 18(8):805-12. PubMed ID: 26542177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Second-line chemotherapy with fotemustine in temozolomide-pretreated patients with relapsing glioblastoma: a single institution experience.
    Scoccianti S; Detti B; Sardaro A; Iannalfi A; Meattini I; Leonulli BG; Borghesi S; Martinelli F; Bordi L; Ammannati F; Biti G
    Anticancer Drugs; 2008 Jul; 19(6):613-20. PubMed ID: 18525321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An overview of fotemustine in high-grade gliomas: from single agent to association with bevacizumab.
    Lombardi G; Farina P; Della Puppa A; Cecchin D; Pambuku A; Bellu L; Zagonel V
    Biomed Res Int; 2014; 2014():698542. PubMed ID: 24800248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Fotemustine (Muphoran) in 22 patients with relapses of high-grade cerebral gliomas].
    Malhaire JP; Lucas B; Simon H; Person H; Dam-Hieu P; Labat JP
    Bull Cancer; 1999 Mar; 86(3):289-94. PubMed ID: 10210763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of fotemustine in recurrent supratentorial malignant gliomas.
    Frenay M; Giroux B; Khoury S; Derlon JM; Namer M
    Eur J Cancer; 1991; 27(7):852-6. PubMed ID: 1834116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multi-institutional phase II study on second-line Fotemustine chemotherapy in recurrent glioblastoma.
    Fabrini MG; Silvano G; Lolli I; Perrone F; Marsella A; Scotti V; Cionini L
    J Neurooncol; 2009 Mar; 92(1):79-86. PubMed ID: 19018476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of second-line fotemustine in elderly patients with recurrent glioblastoma.
    Santoni M; Scoccianti S; Lolli I; Fabrini MG; Silvano G; Detti B; Perrone F; Savio G; Iacovelli R; Burattini L; Berardi R; Cascinu S
    J Neurooncol; 2013 Jul; 113(3):397-401. PubMed ID: 23564276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-dose fotemustine for recurrent malignant glioma: a multicenter phase II study.
    Fabi A; Metro G; Vidiri A; Lanzetta G; Carosi M; Telera S; Maschio M; Russillo M; Sperduti I; Carapella CM; Cognetti F; Pace A
    J Neurooncol; 2010 Nov; 100(2):209-15. PubMed ID: 20352471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cystemustine in recurrent high grade glioma.
    Durando X; Thivat E; Roché H; Bay JO; Lemaire JJ; Verrelle P; Chazal J; Curé H; Chollet P
    J Neurooncol; 2006 Aug; 79(1):33-7. PubMed ID: 16575534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biweekly fotemustine schedule for recurrent glioblastoma in the elderly: activity and toxicity assessment of a multicenter study.
    Addeo R; Lamberti G; Simonetti G; Iodice P; Marinelli A; Montella L; Cappabianca S; Gaviani P; Caraglia M; Prete SD; Silvani A
    CNS Oncol; 2019 Jun; 8(2):CNS32. PubMed ID: 31290692
    [No Abstract]   [Full Text] [Related]  

  • 12. Single-agent Bevacizumab in Recurrent Glioblastoma After Second-line Chemotherapy With Fotemustine: The Experience of the Italian Association of Neuro-Oncology.
    Pasqualetti F; Pace A; Gonnelli A; Villani V; Cantarella M; Delishaj D; Vivaldi C; Molinari A; Montrone S; Pellerino A; Franchino F; Baldaccini D; Lombardi G; Lolli I; Catania F; Bazzoli E; Morganti R; Fabi A; Zagonel V; Bocci G; Fabrini MG; Rudà R; Soffietti R; Paiar F
    Am J Clin Oncol; 2018 Dec; 41(12):1272-1275. PubMed ID: 29782366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fotemustine and recurrent glioblastoma: possible new opportunities for an old drug.
    Addeo R; De Santi MS; Del Prete S; Caraglia M
    Cancer Chemother Pharmacol; 2009 Oct; 64(5):863-6. PubMed ID: 19639315
    [No Abstract]   [Full Text] [Related]  

  • 14. Survival in patients with recurrent glioma as a measure of treatment efficacy: prognostic factors following nitrosourea chemotherapy.
    Rajan B; Ross G; Lim CC; Ashley S; Goode D; Traish D; Brada M
    Eur J Cancer; 1994; 30A(12):1809-15. PubMed ID: 7880611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of recurrent malignant gliomas with fotemustine monotherapy: impact of dose and correlation with MGMT promoter methylation.
    Fabi A; Metro G; Russillo M; Vidiri A; Carapella CM; Maschio M; Cognetti F; Jandolo B; Mirri MA; Sperduti I; Telera S; Carosi M; Pace A
    BMC Cancer; 2009 Mar; 9():101. PubMed ID: 19335893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lecture: fotemustine in brain tumors.
    Silvani A; Gaviani P; Lamperti E; Botturi A; Ferrari D; Simonetti G; Salmaggi A
    Neurol Sci; 2011 Nov; 32 Suppl 2():S255-7. PubMed ID: 21987288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II pilot study of single-agent etirinotecan pegol (NKTR-102) in bevacizumab-resistant high grade glioma.
    Nagpal S; Recht CK; Bertrand S; Thomas RP; Ajlan A; Pena J; Gershon M; Coffey G; Kunz PL; Li G; Recht LD
    J Neurooncol; 2015 Jun; 123(2):277-82. PubMed ID: 25935109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fotemustine in the treatment of brain primary tumors and metastases.
    Khayat D; Giroux B; Berille J; Cour V; Gerard B; Sarkany M; Bertrand P; Bizzari JP
    Cancer Invest; 1994; 12(4):414-20. PubMed ID: 8032964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concurrent radiotherapy: fotemustine combination for newly diagnosed malignant glioma patients, a phase II study.
    Beauchesne PD; Taillandier L; Bernier V; Carnin C
    Cancer Chemother Pharmacol; 2009 Jun; 64(1):171-5. PubMed ID: 19352662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcome after bevacizumab clinical trial therapy among recurrent grade III malignant glioma patients.
    Reardon DA; Herndon JE; Peters K; Desjardins A; Coan A; Lou E; Sumrall A; Turner S; Sathornsumetee S; Rich JN; Boulton S; Lipp ES; Friedman HS; Vredenburgh JJ
    J Neurooncol; 2012 Mar; 107(1):213-21. PubMed ID: 21997879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.